<DOC>
	<DOCNO>NCT00441610</DOCNO>
	<brief_summary>CLBQ707A1101 assess tolerability , safety , efficacy pharmacokinetics gimatecan Japanese patient .</brief_summary>
	<brief_title>An Extension Trial Phase I Dose Escalation Study Gimatecan Administered Orally 5 Consecutive Days Japanese Patients With Advanced Solid Tumor</brief_title>
	<detailed_description />
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Inclusion criterion : Patients complete core protocol ( CLBQ707A1101 , NCT00410358 ) exhibit stable disease , partial complete response define core protocol . If patient nonmeasurable lesion , he/she must exhibit progressive disease Exclusion criterion : Documented progressive disease define core protocol Patients performance status 3 4 ECOG scale Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Gimatecan</keyword>
	<keyword>topoisomerase I inhibitor</keyword>
	<keyword>advanced solid tumor</keyword>
</DOC>